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Abstract
Reports that bacteria within the Firmicutes phylum, especially the species
Faecalibacterium prausnitzii, are less abundant in Crohn’s disease (CD) patients
and supernatants from cultures of this bacterium are anti-inﬂammatory prompted
the investigation of the possible correlations between the abundance of F.
prausnitzii and the response to treatment in patients with gut diseases and healthy
controls. In a randomized, double-blind trial, faeces were collected from healthy
volunteers, and from patients with active CD, ulcerative colitis (UC) and irritable
bowel syndrome before and after treatment. The levels of F. prausnitzii DNA in
faecal suspensions were determined by PCR. Treatment by an elemental diet was
effective, resulting in decreases in both the Harvey and Bradshaw index
(Po0.001) and the concentrations of serum C-reactive protein (Po0.05). The
total levels of F. prausnitzii in faecal samples from CD patients at presentationwere
lower than those in the other groups both before and after the treatment. There
was no correlation between F. prausnitzii abundance and the severity of CD before
treatment. Clinical improvement unexpectedly correlated with a signiﬁcant
decrease in the abundance of F. prausnitzii, especially the A2-165 subgroup
(Po0.05). Our data suggest that a paucity of F. prausnitzii in the gastrointestinal
microbial communities is likely to be a minor aetiological factor in CD: recovery
following elemental diet is attributed to lower levels of gut ﬂora.
Introduction
The cause of Crohn’s disease (CD) is unknown and successful,
long-term treatment represents considerable clinical and phar-
macological challenges. The conventional treatment of disease
of mild to medium severity consists of antibiotics to counteract
infection and 5-aminosalicylic acid (5-ASA) with or without
corticosteroids to counter inﬂammation, but remission can also
be achieved with enteral feeding (King et al., 1997). The faecal
bacterial ﬂora in CD is known to be abnormal (Sartor, 2008).
CD has been suggested to be an autoimmune disease with an
immune attack directed against the resident bacteria of the
colon (Macpherson et al., 1996). The coating of colonic bacteria
with immunoglobulin approaches 100% in active CD, as
compared with 20% in healthy subjects and patients with
irritable bowel syndrome (IBS). After enteral feeding, this
coating is rapidly reduced (van der Waiij et al., 2004).
Thereis increasing evidence thatgut microorganisms play
key roles in gastrointestinal disease (Sartor, 2006; 2008).
Some are believed to generate a harmful toxin (Pitcher &
Cummings, 1996; Loubinoux et al., 2002). Many others are
known to yield butyrate, which is not only an essential
energy source for colonocytes (Chapman et al., 1994;
Costello et al., 1994; Macpherson et al., 1996; Aminov
et al., 2006; Louis & Flint, 2009; Mai & Draganov, 2009)
but also is both anti-inﬂammatory and anticarcinogenic
(Hamer et al., 2008; Tazoe et al., 2008). Therefore, consider-
able interest has been generated by reports that a reduction
in bacteria within the Firmicutes phylum, especially the
species Faecalibacterium prausnitzii, has been observed in
the gut of CD patients and that supernatants from cultures
of this bacterium are anti-inﬂammatory (Sokol et al., 2008).
Because oxidation of butyrate is the major source of ATP in
cells lining the colon (Yin et al., 2001), decreased levels of
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SF. prausnitzii could well reduce ATP within these cells. At the
same time, coupled with the loss of anti-inﬂammatory
agents from F. prausnitzii, this would, in a double blow,
weaken the ability of the cells to ﬁght infection (Smith et al.,
2008). Thus, these ﬁndings potentially shed light on the
aetiology of CD and offer a novel therapeutic approach
involving recolonization of the gut with the bacterium.
To evaluate these ﬁndings and to assess the effects of
elemental diet therapy (ED) on the population of F. praus-
nitzii within the gut, faecal samples were collected before
and after therapy from patients suffering from CD, IBS and
ulcerative colitis (UC) as disease control groups, and also
from healthy controls.
Materials and methods
Patients and control subjects
Twenty patients diagnosed to be suffering from CD, 21
patients with IBS, 14 patients with UC and 18 healthy
subjects as controls were recruited at Addenbrookes Hospi-
tal, Cambridge, which functions as a tertiary referral centre
for inﬂammatory bowel disease. A faecal sample and a blood
sample were taken at the start of the treatment and again
(except for the controls) 2 weeks later. Faecal samples were
collected at the homes of patients and control subjects and
immediately stored at 41C. Samples were taken to Adden-
brookes Hospital, assigned undisclosed identiﬁcation codes
and sent by courier at 41C to the University of Birmingham
for DNA extraction, arriving within 48h of collection.
Sample identiﬁcations were decoded only after data collec-
tion had been completed. Ethical permission to collect these
samples was obtained from Leeds West Ethics Research
Committee, ref. 07/Q1205/39, and informed, written con-
sent was obtained from each subject.
Treatment regimes and assessment of the
effects of treatment
Most CD patients attending the Addenbrookes Hospital
tertiary referral clinic were considered to be relatively
complex cases that had proved refractory to previous
pharmacological treatments. These included steroids and/
or immuno modulation therapy (azathioprine or metho-
trexate), or 5-ASA. Treatment was chosen by the individual
consultant supervising each case, but all included in the
present study were given ED (King et al., 1997). All normal
food items were withdrawn and patients were maintained
for 2 weeks on ED (E 028 Extra, Scientiﬁc Hospital Supplies
International, Liverpool, UK), which contains a predigested
mixture of amino acids, malto-dextrins, minerals and
vitamins, with a single fat source, rape seed oil. Thus, no
additional complex carbohydrate or protein was provided
for the gut ﬂora to use as energy substrates other than
endogenous sources, for example, protein released from
sloughed cells. Water ad libitum was the only other item
allowed. The nutritional requirements were individually
calculated using the Schoﬁeld equation (Schoﬁeld, 1985).
The efﬁcacy of treatment was assessed on symptoms using
the Harveyand Bradshaw index (Harvey & Bradshaw, 1980),
and by an assay of serum C-reactive protein (CRP) as a
measure of inﬂammatory stress.
None of the UC and IBS patients was given ED. Eleven of
the UC patients had received either immuno-modulation or
5-ASA therapy before this study, and this was continued,
albeit with changes in the drugs and increases in the doses
used. Treatment-naı ¨ve patients were placed on similar regi-
mens. IBS patients received conventional treatment.
The Harvey and Bradshaw index and the Walmsley index
were used to determine the severity of CD and UC,
respectively.
DNA extraction
DNA was extracted from each faecal sample (0.2g) using a
QIAamp DNA stool Mini Kit (Qiagen) by following the
manufacturer’s instructions. Extracted DNA was stored in
aliquots at  201C. DNA quality was assessed by determin-
ing the ratio of A260nm to A280nm.
PCR amplification of bacterial DNA
Two subgroups of F. prausnitzii have been identiﬁed on the
basis of their published whole-genome DNA sequences.
Primers Fp.ID.F2 (GTGACCGGATCGAACGACC) and
Fp.ID.R2 (TCCAGGTCATGTGGGCAGC) were designed
against the nucleotidyl transferase gene and the butyryl-
CoA transferase gene, respectively, using the nucleotide
sequences of both F. prausnitzii A2-165 and M21/2. Ampli-
cons from the two F. prausnitzii subgroups could be
generated simultaneously within a single PCR reaction and
distinguished by the fragment length: approximately 650bp
for the A2-165-related subgroup and 778bp for the M21/2-
related subgroup.Foreach PCRampliﬁcation, 50ngof DNA
was used as a template with HotStarTaq Plus Master Mix Kit
(Qiagen) plus 4mL of Q-solution (Qiagen) according to the
manufacturer’s instructions. The reaction conditions were:
initial denaturation (5min at 951C), then 35 cycles of
denaturation (1min at 941C), annealing (1min at 581C)
and elongation (1min at 721C) and a ﬁnal extension
(10min at 721C).
For samples from which F. prausnitzii was not ampliﬁed,
the quality of the DNA was conﬁrmed using 50ng of DNA
as template in a second PCR with the primers 27F (50-AG
AGTTTGATCATGGCTCAG-30) and 1492R (50-GGTTACC
TTGTTACGACTT-30) that annealed to bacterial DNA en-
coding 16S rRNA gene (Lane, 1991). These primers amplify
a highly conserved region in the DNA from many bacterial
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follows: initial denaturation (5min at 951C), then 35 cycles
of denaturation (30s at 941C), annealing (1min at 551C)
and elongation (2min at 721C) and a ﬁnal extension (8min
at 721C). The reaction mixture was the same as stated
above.
Quantification of amplified DNA
Because the same amount of template DNA, 50ng, was
added to each PCR, the differing brightness of the bands
on the gel was used as an indicator of the amount of F.
prausnitzii in each patient. The intensity of the bands was
measured using the software QUANTITY ONE (Bio-Rad) and
quantiﬁed by comparison with known amounts of a 1-kb
ladder (New England Biolabs). The experiment was repeated
once. Samples that failed to yield a PCR product were
reassayed a third or a fourth time, and the quality of the
DNAwas conﬁrmed by ampliﬁcation of bacterial 16S rRNA
gene.
Serum CRP assay
Serum CRP levels were determined by the Clinical Biochem-
istry Department, Addenbrookes Hospital.
Statistical analyses
The results were assessed using nonparametric methods.
The results of the estimated amount of each subgroup of
F. prausnitzii DNA generated by PCR ampliﬁcation for the
three patient groups both pre- and post-treatment and the
control group were analysed separately using Kruskal–Wal-
lace one-way ANOVAand Dunn’s post hoc all comparisons test.
To gain an estimate of the effects of illness on the total
amount of F. prausnitzii, the results for the controls and the
three pretreatment samples were ranked ﬁrst for the M21/2
subgroup (the larger PCR fragment) and then for the A2-
165 subgroup (the smaller PCR product), and the two
ranking values for each sample were added together to yield
a combined rank value that was regarded as an estimate of
the total F. prausnitzii content of the faeces. Post-treatment
samples were analysed in the same way. These two new data
sets were also analysed using the Kruskal–Wallace one-way
ANOVA and Dunn’s post hoc all comparisons. Paired data were
analysed using the Wilcoxon signed rank-sum (WSRS) test.
Kruskal–Wallace analyses were carried out initially using the
MINITABS statistical package. Data were then reanalysed using
the INSTAT (Graphpad) program, which was also used for
Dunn’s post hoc all comparisons (but completed only if the
two-tailed P value was o0.05 in the Kruskal–Wallace
analysis), Mann–Whitney tests for unpaired data, the WSRS
test for paired data and Spearman r to determine the level of
correlation between parameters.
Results
The results are summarized in Tables 1 and 2. The original
data on which these tables are based are available as
Supporting Information, Tables S1–S3 in the online version
of this article.
Subject characteristics
The patient groups consisted of 20 patients diagnosed as
suffering from CD, 21 patients with IBS and 14 patients with
UC. They were recruited at Addenbrookes Hospital, Cam-
bridge, which functions as a tertiary referral centre for
inﬂammatory bowel disease. The patients gave a faecal and
a blood sample at the start of the treatment and again 2
weeks later. In addition, blood and faecal samples were
obtained from 18 healthy subjects as controls.
Effects of treatment on the clinical state
Eighty-four per cent of the initial group of CD patients
returned to follow-up clinics. The effects of treatment were
beneﬁcial, as evidenced by decreases in the Harvey and
Bradshaw scores of individual patients (Po0.0001; WSRS
test). At presentation, all 15 patients whose serum was
assayed had serum CRP levels above the upper limit of the
reference range (6mgL
 1). Following treatment, there was a
signiﬁcant decline in the CRP levels (Po0.05, WSRS test).
Quantification of F. prausnitzii-specific PCR
products
Bacterial DNA was obtained from each faecal sample. The
same amount of faecal DNA was used as a template in PCR
reactions with the primer pair Fp.ID.F2 and Fp.ID.R2 to
detect the presence of F. prausnitzii. Although the total
quantity of F. prausnitzii PCR products and the ratio of the
two subgroups varied considerably from sample to sample
(Fig. 1), only a minority of samples failed to yield one or
both F. prausnitzii PCR products. The sequences of PCR
products were 100% identical to those of the published
Table 1. Yields of PCR products related to the two Faecalibacterium
prausnitzii subgroups from the different patient groups
Group N
A2-165 subgroup M21/2 subgroup
Mean SD Mean SD
Control 18 170 135 248 161
CD before treatment 20 103 103 127 144
CD after treatment 20 44 74 113 138
UC before treatment 14 170 147 149 164
UC after treatment 14 157 162 175 164
IBS before treatment 21 202 162 246 149
IBS after treatment 21 180 131 214 111
N, number of samples; Means, average yield (ng) of PCR product
generated; SD, SD within the sample.
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When no F. prausnitzii product was detectable, a second
ampliﬁcation to produce an amplicon from the DNA
encoding the 16S rRNA gene was always successful, demon-
strating that the bacterial DNA extracted was of good
quality.
Comparison of F. prausnitzii abundance in the
faecal samples
There were no signiﬁcant differences in the levels of the A2-
165 subgroup of F. prausnitzii in the three treatment groups
at initial presentation and in the control group (Kruskal–
Wallace P=0.248, adjusted for ties), although the levels for
CD patients were the lowest of the four groups. There was a
signiﬁcant difference among the three post-treatment and
control groups (Kruskal–Wallace P=0.006, adjusted for
ties), with the levels for the CD group being signiﬁcantly
lower than those of the control group (Dunn’s post hoc test
Po0.05). For the CD group, the levels had decreased
signiﬁcantly post-treatment (WSRS test P=0.0046).
The levels of the M21/2 F. prausnitzii subgroup were
analysed similarly. There was a signiﬁcant difference among
the three pretreatment patient groups and the control group
(Kruskal–Wallace P=0.029, adjusted for ties), although the
post hoc test revealed no signiﬁcant difference when indivi-
dual groups were compared with each other, despite lower
values for both the CD and the UC samples. However, for
this F. prausnitzii subgroup, the levels in the CD patients
were signiﬁcantly lower than those in the control samples, as
judged by the Mann–Whitney test (P=0.02). Following
treatment, there was also a signiﬁcant difference in the levels
of the M21/2 subgroup among the three patient groups and
the control group (Kruskal–Wallace P=0.034, adjusted for
ties). The levels in the CD group were signiﬁcantly lower
than those in controls (Dunn’s post hoc Po0.05), although
the difference between the pre- and the post-treatment levels
(median before treatment 77 compared with 65.5 post-
treatment) was not signiﬁcantly different (WSRS P=0.61).
Thus, the levels of both F. prausnitzii subgroups for
CD patients either decreased or remained low rather
than increased following successful treatment with an
enteral diet.
It is obvious from Fig. 1 that there were wide differences
between the ratios of the levels of the two F. prausnitzii
subgroups between patient samples. However, the overall
total levels of each subgroup were similar, and so it was
appropriate to lend equal weight to the two subgroups to
compare the total levels of F. prausnitzii among the patient
and control populations. The analyses revealed that the total
levels of F. prausnitzii in CD patients were signiﬁcantly lower
than those in the other groups both before and after
treatment (Kruskal–Wallace test Po0.005 before treatment
and o0.001 after treatment; Dunn’s comparisons for the
CD group relative to the control group Po0.05 before
treatment; o0.001 after treatment).
Table 2. Kruskal–Wallis test for data on the abundance of the Faecalibacterium prausnitzii subgroup in different groups of patients
Group N
A2-165 subgroup M21/2 subgroup
Median Average rank Z value Median Average rank Z value
Control vs. before treatment 18 178 39.3 0.52 275 43.9 1.60
Control vs. after treatment 18 178 42.8 1.32 275 45.3 1.90
CD before treatment 20 77 29.1  1.95 77 28.3  2.16
CD after treatment 20 0 23.4  3.36 66 26.5  2.61
UC before treatment 14 177 38.4 0.28 110 30.2  1.33
UC after treatment 14 141 38.4 0.27 154 34.9  0.42
IBS before treatment 21 180 41.6 1.18 241 43.9 1.76
IBS after treatment 21 192 44.1 1.32 197 41.4 1.13
100 bp ladder
600 bp 
800 bp 
M21/2 (778 bp)
A2-165 (650 bp)
Fig. 1. Relative quantity of Faecalibacterium prausnitzii in faecal DNA determined by PCR. Agarose gel showing bands of the F. prausnitzii amplicon
from 22 faecal samples. The upper band of 778bp corresponds to the M21/2 subgroup; the lower 650bp band corresponds to the A2-165 subgroup.
The same amount of template DNA was added to each PCR reaction, and so these differences indicate the relative amount of F. prausnitzii in each
patient. Where a PCR product was present, the brightness of the band was measured using the software QUANTITY ONE (Bio-Rad) and converted to DNA
amount by reference to a 1kb ladder (New England Biolabs: right-hand lane).
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F. prausnitzii and clinical assessment
The levels of each subgroup of F. prausnitzii in CD patients
were analysed for correlation with clinical status, as deter-
mined by the Harvey and Bradshaw scores, both before and
after treatment. The data were assessed using the nonpara-
metric Spearman r coefﬁcient. As the r value for the A2–165
subgroup was 0.018 (P=0.3) and r=0.02 (P=0.92) for the
M2/21 group, neither set of F. prausnitzii levels correlated
with clinical status.
Further analysis of data from samples from the
UC patients
The data for UC patients before treatment appeared to show
that the levels of the F. prausnitzii M2/21 subgroup were
lower those than in the control group, but the statistical tests
used failed to establish that the difference was signiﬁcant.
We therefore used the nonparametric Mann–Whitney test to
compare the data for this UC subgroup with the controls. As
the resulting P value, 0.087, tended towards, but did not
conﬁrm that the difference was signiﬁcant, this is probably a
type 2 error: more data are required for this patient group.
Discussion
Previous studies have established that Firmicutes are domi-
nant among the diverse range of butyrate-producing bacter-
ia in the human gut, with ﬁve species being especially
abundant: Eubacterium rectal; Roseburia faecis; Eubacterium
hallii; an unnamed but cultured species, SS2/1; and F.
prausnitzii (Aminov et al., 2006; Louis et al., 2009). The
report that the levels of F. prausnitzii in the gut of patients
with CD were lower than the levels in healthy subjects was
based on analysis of tissue taken from patients undergoing
elective surgery (Sokol et al., 2008). The current study used
an alternative way of identifying bacteria present in the
human gut, which was to investigate the bacterial compo-
nent of faecal samples. However, analysis of faecal DNA in
the present study only partially conﬁrmed these earlier
ﬁndings. Although F. prausnitzii, especially the M21/2 sub-
group, were less abundant in CD patients at presentation
than in the control group, contrary to expectation, success-
ful treatment of the CD group resulted in a decrease rather
than an increase in F. prausnitzii abundance. It is an open
question as to whether the treatment received by CD
patients before attendance at the Addenbrookes clinic might
have resulted in the statistically signiﬁcant decline in the
faecal levels of F. prausnitzii: a recent study strongly suggests
that this might be the case (Benus et al., 2010). However, the
subsequent decline following ED treatment clearly excludes
the possibility that recovery might be due to an increase in
F. prausnitzii levels within the gut and the consequent
increase in immuno-suppressive agents secreted by the
bacteria (Sokol et al., 2008).
The causes of CD and other gastrointestinal diseases are
clearly multifactorial, and it is therefore not surprising that
the same is true of mechanisms that protect against disease.
The previous report clearly established that the positive
effect of F. prausnitzii in deterring the recurrence of CD
following surgery was due to the production of an unidenti-
ﬁed metabolite other than butyrate (Sokol et al., 2008).
Bacteria generate butyrate during fermentation of lactate,
but lactate is also the preferred energy source of many other
bacteria, including propionibacteria, acetogens and sul-
phate-reducing bacteria (Macpherson et al., 1996). In the
current study, patients were treated nutritionally with a
minimal diet that would decrease the availability of lactate
and hence also decrease the bacterial ﬂora, including F.
prausnitzii (Chapman et al., 1994; Costello et al., 1994; King
et al., 1997; Whelan et al., 2005; Johnson et al., 2006). It is
known that faecal bacterial dry weight in healthy volunteers
fed ED declines drastically (Costello et al., 1994). A positive
outcome following treatment might therefore be due to a
greater reduction in the production of toxic, inﬂammatory
metabolites by other bacteria relative to any negative effects
of a decreased population of butyrate-producing bacteria.
For example, decreased availability of lactate would select
against sulphate-reducing bacteria such as Desulfovibrio
piger, which is abundant in human faeces and the major
source of sulphide, which inhibits butyrate oxidation by
colonocytes (Pitcher & Cummings, 1996; Roediger et al.,
1997; Willis et al., 1997; Levine et al., 1998; Loubinoux
et al., 2002; Duncan et al., 2004; Fite et al., 2004; Marquet
et al., 2009).
The different results reported in this and the previous
study may have arisen from the differences in the material
assayed. Normally produced stools, which were used in this
study, represent bacterial populations chieﬂy along the
colon, whereas the surgically resected material in the earlier
study were from higher up the alimentary canal. Bacterial
populations in the two sites may well differ. Furthermore,
patients awaiting surgery may have been given enteral or
parenteral feeds to improve their state of nutrition or fasted
preoperatively. If the organism is dependent on dietary
complex carbohydrate, these also could have been factors
leading to the low numbers of F. prausnitzii reported.
In conclusion, the clinical improvement in our patients
with CD was associated with a decline in the numbers of F.
prausnitzii, but this does not mean that the organism can be
considered to be a pathogen responsible for producing CD,
as it was equally frequent in our healthy volunteers. It is
more likely to be an innocent bystander, whose numbers
decline with ED feeding, which exerts its effects in CD
through its action on the gut microbial communities
(Hunter, 1991). We therefore attribute the decrease in the
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fact that this diet reduces the undigested food residues
required to sustain normal levels of ﬂora in the lower gut,
particularly bacteria such as F. prausnitzii. Such a change in
ﬂora was associated with the marked improvement seen in
patients’ symptoms and the levels of CRP. We suggest,
therefore, that this reduction in gut ﬂora was chieﬂy
responsible for the patients’ improvement.
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